Cargando…

Frequency and Mutation Patterns of Resistance in Patients with Chronic Hepatitis B Infection Treated with Nucleos(t)ide Analogs in Add-On and Switch Strategies

BACKGROUND: Treatment for chronic hepatitis B (CHB) has improved over the last 10 years mainly due to the development of effective oral antiviral agents [nucleoside/nucleotide analogs (NUCs)]. OBJECTIVES: The aim of the present study is to identify the frequency and major patterns of resistance to t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sayan, Murat, Akhan, Sila Cetin, Senturk, Omer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3234585/ https://www.ncbi.nlm.nih.gov/pubmed/22224083 http://dx.doi.org/10.5812/kowsar.1735143X.775

Ejemplares similares

Monitoring and comorbidities in patients with chronic hepatitis B currently treated with nucleos(t)ide analogs
por: Siakavellas, Spyros, et al.
Publicado: (2021)

High percentage atypical hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogs
por: Lin, Ching-Chung, et al.
Publicado: (2019)

The efficiency of low-dose hepatitis B immunoglobulin plus nucleos(t)ide analogs in preventing posttransplant hepatitis B virus recurrence
por: VATANSEVER, Sezgin, et al.
Publicado: (2019)

Genotype A2/adw2 Strain of Hepatitis B Virus in Turkey
por: Sayan, Murat, et al.
Publicado: (2010)

The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs
por: Gupta, Nidhi, et al.
Publicado: (2014)

Impact of nucleos(t)ide analog treatment on the development of malignancy in patients with chronic hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2018)

Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss
por: Xue, Yan, et al.
Publicado: (2021)

Predictors of Sustained Virologic Response after Discontinuation of Nucleos(t)ide Analog Treatment for Chronic Hepatitis B
por: Peng, Jie, et al.
Publicado: (2015)

Clinical features of hepatocellular carcinoma with hepatitis B virus among patients on Nucleos(t) ide analog therapy
por: Liu, Li
Publicado: (2020)

Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2021)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy
por: Osiowy, Carla, et al.
Publicado: (2016)

Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs
por: Li, Tao, et al.
Publicado: (2018)

The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients
por: Xu, Wen-Xiong, et al.
Publicado: (2021)

Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog
por: Hui, Vicki Wing-Ki, et al.
Publicado: (2021)

Corrigendum: Increasing Number of Individuals Receiving Hepatitis B nucleos(t)ide Analogs Therapy in Germany, 2008–2019
por: Maisa, Anna, et al.
Publicado: (2022)

Renal Function in Nucleos(t)ide Analog-Treated Patients With Chronic Hepatitis B: A Systematic Literature Review and Network Meta-Analysis
por: Chan, Henry L. Y., et al.
Publicado: (2016)

Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients
por: He, Li-Ting, et al.
Publicado: (2016)

HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study
por: Hu, Peng, et al.
Publicado: (2018)

Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B
por: Kim, Soon Sun, et al.
Publicado: (2011)

Dynamics of Serum Pregenome RNA in Chronic Hepatitis B Patients Receiving 96-Month Nucleos(t)ide Analog Therapy
por: Tao, Yachao, et al.
Publicado: (2022)

Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy
por: Murata, Ayato, et al.
Publicado: (2022)

Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B
por: Lee, I-Cheng, et al.
Publicado: (2015)

The Impact of Nucleos(t)ide Analogs Off-Therapy Among Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis
por: Wang, Mian, et al.
Publicado: (2021)

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs
por: Cai, Shaohang, et al.
Publicado: (2018)

Impact of antiviral therapy with nucleos(t)ide analog on survival of patients with HBV-related small hepatocellular carcinomas
por: Wei, Yanyan, et al.
Publicado: (2019)

Antiviral activities of two nucleos(t)ide analogs against vaccinia and mpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

Management of chronic hepatitis B patients: Efficacy & limitation of nucleos(t)ide analogues
por: Inoue, Jun, et al.
Publicado: (2011)

The impact of newer nucleos(t)ide analogues on patients with hepatitis B decompensated cirrhosis
por: Cholongitas, Evangelos, et al.
Publicado: (2015)

Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients?
por: Moreno-Cubero, Elia, et al.
Publicado: (2018)

Distinct histological patterns in chronic hepatitis D with nucleos(t)ide analogue therapy
por: Hercun, Julian, et al.
Publicado: (2023)

Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients
por: Zhang, Chi, et al.
Publicado: (2016)

Hepatocellular Carcinoma in Chronic Hepatitis B Patients on Third Generation Nucleos(t)ides Analogs: Risk Factors and Performance of a Risk Score
por: Magalhães-Costa, Pedro, et al.
Publicado: (2016)

Prevalence and Associated Factors of Low-Level Viremia in Chronic Hepatitis B Patients After Long-Term Therapy with Nucleos(t)ide Analogs
por: Han, Jiajia, et al.
Publicado: (2023)

Circulating miR-122 Is a Predictor for Virological Response in CHB Patients With High Viral Load Treated With Nucleos(t)ide Analogs
por: Wu, Yin, et al.
Publicado: (2019)

Clinical and Virological Efficacy of Etravirine Plus Two Active Nucleos(t)ide Analogs in an Heterogeneous HIV-Infected Population
por: López-Cortés, Luis F., et al.
Publicado: (2014)

Antiviral activities of two nucleos(t)ide analogs against vaccinia, mpox, and cowpox viruses in primary human fibroblasts
por: Dsouza, Lara, et al.
Publicado: (2023)

Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study
por: Wu, Feng-Ping, et al.
Publicado: (2020)

Serum Hepatitis B Virus RNA Levels Predict HBeAg Seroconversion and Virological Response in Chronic Hepatitis B Patients with High Viral Load Treated with Nucleos(t)ide Analog
por: Ji, Xin, et al.
Publicado: (2020)

Comparison of First-year Results of Tenofovir and Entecavir Treatments of Nucleos(t)ide-naive Chronic Hepatitis B Patients with Hepatosteatosis
por: Dogan, Zeynal, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ldr4ala8i7v3sh3su3sk40801v